1. A novel fusion protein candidate for the serodiagnosis of Mycoplasma agalactiae infection
- Author
-
Malihe Akbarzadeh-Niaki, Abdollah Derakhshandeh, Nasrin Kazemipour, and Farhid Hemmatzadeh
- Subjects
Mycoplasma agalactiae ,Rodent Diseases ,Mice ,Vaccines ,Bacterial Proteins ,General Veterinary ,Recombinant Fusion Proteins ,Animals ,Female ,Mycoplasma Infections ,General Medicine ,Antigens ,Recombinant Proteins - Abstract
Background The aim of current study was to construct, express, purify and immunogenicity evaluate of a novel recombinant fusion protein including Pyruvate dehydrogenase beta subunit (PDHB) and high antigenic region of lipoprotein P80 of Mycoplasma agalactiae. Using bioinformatics tools, antigenicity and physiochemical properties of fused protein were assessed. Material and methods The recombinant fusion protein of GST-PDHB-P80 were expressed in pGEX4T-1 and purified then verified by Western blot assay. The purified protein was successfully used for immunization of mice. 30 female BALB/c mice were divided into three groups (10 mice per each group) injected with GST-PDHB-P80, inactivated bacteria vaccine and PBS as negative control, separately. Results Western blot analysis confirmed the interaction between the immunized mice serum and the blotted recombinant protein GST-PDHB-P80, demonstrating the immunogenicity of this protein. Moreover, the sera of vaccinated mice with inactivated bacteria vaccine, containing whole cell proteins, detected the recombinant protein GST-PDHB-P80 confirming the antigenicity of PDHB-P80. Negative control displayed no reactivity with GST-PDHB-P80. Conclusion We proposed a novel designed chimeric protein of Mycoplasma agalactiae as a potential marker for serodiagnostic assays but still further field research is required.
- Published
- 2022
- Full Text
- View/download PDF